XNYSKVUE
Market cap41bUSD
Dec 24, Last price
21.56USD
1D
-0.14%
1Q
-6.26%
IPO
-18.64%
Name
Kenvue Inc
Chart & Performance
P/E
24.84
P/S
2.68
EPS
0.87
Div Yield, %
35.21%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
15.44b
+3.30%
Net income
1.66b
-19.38%
CFO
3.17b
+25.47%
Dividend
Aug 14, 20240.205 USD/sh
Earnings
Feb 06, 2025
Profile
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
IPO date
May 04, 2023
Employees
22,000
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 15,444,000 3.30% | 14,950,000 -0.69% | 15,054,000 4.06% | ||
Cost of revenue | 12,882,000 | 12,673,000 | 12,474,000 | ||
Unusual Expense (Income) | |||||
NOPBT | 2,562,000 | 2,277,000 | 2,580,000 | ||
NOPBT Margin | 16.59% | 15.23% | 17.14% | ||
Operating Taxes | 526,000 | 550,000 | 894,000 | ||
Tax Rate | 20.53% | 24.15% | 34.65% | ||
NOPAT | 2,036,000 | 1,727,000 | 1,686,000 | ||
Net income | 1,664,000 -19.38% | 2,064,000 -0.67% | 2,078,000 -336.41% | ||
Dividends | (14,554,000) | ||||
Dividend yield | 35.30% | ||||
Proceeds from repurchase of equity | 4,241,000 | ||||
BB yield | -10.29% | ||||
| Debt | |||||
Debt current | 643,000 | 35,000 | 129,000 | ||
Long-term debt | 7,925,000 | 197,000 | 211,000 | ||
Deferred revenue | 214,000 | (82,000) | |||
Other long-term liabilities | 754,000 | 646,000 | 1,058,000 | ||
Net debt | 7,115,000 | (1,065,000) | (474,000) | ||
| Cash flow | |||||
Cash from operating activities | 3,168,000 | 2,525,000 | 334,000 | ||
CAPEX | (469,000) | (375,000) | (295,000) | ||
Cash from investing activities | (488,000) | (390,000) | (171,000) | ||
Cash from financing activities | (2,527,000) | (1,583,000) | |||
FCF | 2,388,000 | 1,253,000 | (1,197,000) | ||
| Balance | |||||
Cash | 1,382,000 | 1,231,000 | 740,000 | ||
Long term investments | 71,000 | 66,000 | 74,000 | ||
Excess cash | 680,800 | 549,500 | 61,300 | ||
Stockholders' equity | (4,929,000) | (5,434,000) | 20,399,000 | ||
Invested Capital | 25,321,000 | 26,102,000 | 21,167,700 | ||
ROIC | 7.92% | 7.31% | 8.26% | ||
ROCE | 11.13% | 9.86% | 10.90% | ||
| EV | |||||
Common stock shares outstanding | 1,915,057 | 1,914,894 | 1,888,973 | ||
Price | 21.53 | ||||
Market cap | 41,231,178 | ||||
EV | 48,346,178 | ||||
EBITDA | 3,189,000 | 2,921,000 | 3,311,000 | ||
EV/EBITDA | 15.16 | ||||
Interest | 358,000 | ||||
Interest/NOPBT | 13.97% | ||||